Serious inefficiencies are hampering clinical trials of new drugs and treatments, prolonging the suffering of millions. Today’s platform technologies, says Dr. Harsha Rajasimha of Jeeva Informatics, enables more flexible trials that are faster, more efficient, and
The outbreak of the COVID-19 pandemic seriously disrupted new drug testing, treatments, and in-person healthcare services; access to clinical trial sites was reduced by some 80%.1 Emerging technology enables patients to interact with the clinical trial
Leaders from the trial tech provider discuss how human-focused technology on eClinical platforms can tackle inefficiencies associated with traditional studies. According to Harsha Rajasimha, CEO and founder of Jeeva Informatics, clinical trials often are plagued by
Serious inefficiencies are hampering clinical trials of new drugs and treatments, prolonging the suffering of millions. Today’s platform technologies, says Dr. Harsha Rajasimha of Jeeva Informatics, enables more flexible trials that are faster, more efficient, and
Did you know that 80% of participants of randomized, controlled clinical trials are Caucasian males or that less than 10% of those trials included children? Furthermore, women and minorities are much less likely to participate in
The clinical trial industry must proactively address a record of “historical errors and misbehavior” in its treatment of minority populations if it wants to rebuild trust and increase patient involvement, says Dr. Harsha Rajasimha of Jeeva
Before medications and treatments can be deemed safe and effective for the masses, they are rigorously studied in a process called clinical trials. During clinical trials, medical professionals move through four testing phases to evaluate how
Clinical trials of new drugs and treatments have a high failure rate. Better planning and technology-aided communication, says Dr. Harsha Rajasimha of Jeeva Informatics, can significantly reduce the number of participants who drop out, thus improving
LUZERNE COUNTY, Pa. — Right now, there are clinical trials for COVID-19 treatments, as well as treatments for all kinds of other medical issues. The problem, according to some, is that mostly middle-aged white men are
“It’s not reasonable, ethical, or fair to expect patients to go to a physical site when it’s not necessary” for the conduct of a clinical trial, says Harsha Rajasimha, founder and CEO of Jeeva Informatics Solutions.
